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Materials and method. We analyze 133 patients staged IIa–IIIc. 59 pts in VP, 74 pts in SP. Groups were well balanced. There were
less stages II (9% vs. 29%) and stages III (34% VS. 35%) in VP than in SP p<0.0001. All pts were treated to a total dose of 50.4Gy and
concomitant ﬂuoropyrimidine-based chemotherapy. A dedicated colorectal team of surgeons underwent all MRS in our hospital.
We analyze pts for overall survival (OS) and disease free survival (DFS).
Results. Median follow up was 3.25 years (0.25–9.28) OS at 2 and 5 years: 82%, 74%. OS cancer-speciﬁc (CA) at 2 and 5 years: 90%,
78%. Mean DFS global was: 7.05 years (IC 95%: 6.31–7.79). Mean DFS local relapse was: 8.17 years (IC 95: 7.59–8.75). Mean OS VP
vs. SP was 3.68 vs. 7.34 years hazard ratio (HR) = 1.068, p=ns. OS (CA) VP vs. SP 3.9 vs. 7.9 years, HR=1.07, p=ns. Mean DFS VP
vs. SP 3.7 vs. 6.83, HR=1.49, p=ns. Mean DFS (local relapse) VP vs. SP 3.88 vs. 8.08 years HR=1.26, p=ns. Pts whose pathological
stage was higher (PG) than clinical stage had worse OS survival than those with non-response (NR) or any response (AR): PG=5.14
years vs. NR=6.2 vs. AR=7.55, p<0.05.
Conclusion. Patients included in VP suffer from more advanced disease than PS, yet their OS and DFS were equivalent.
http://dx.doi.org/10.1016/j.rpor.2013.03.212
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Introduction and objectives. In 2011, following the preliminary results of the CROSS trial, published in late 2010 our unit esopha-
gogastric cancer treatment decided to start with this promising protocol. In our case we intend to ﬁnd out if you may get better
results than the previous protocol used in our center RTCT including cisplatin and 5FU-in 2nd place if possible with a lower
mortality.
Material and methods. We included 10 patients where it has established the possibility of preoperative treatment as inclusion
exclusion criteria of the protocol, respecting the guidelines of dose and schedule recommended.
Results. The 50% of patients had TNM stage, T3N1M0 while the remaining 50% were T3N0M0. The predominant histology was
adenocarcinoma of the lower esophageous-cardia in 90%.Mean agewas 58 years (range 35–75 years) 90% of the patients improved
from the dysphagia symptoms, not requiring entrance feeding tube or in any case admittance at hospital. Surgery was performed
at 6 weeks CTRT ﬁnish. Presented a low rate of complications: only 1 patient (10%) had wound dehiscence. Another patient
had hypoxemia secondary to bilateral basal atelectasis (10%). 0% mortality. In 100% of patients after CTRT understaging was
objectiﬁed. The majority of patients had R0 resection. And pathological stage. Most frequent was yPT1a-bN0M0 The results in
terms of survival are not mature
Conclusions. In principle it is a secure protocol agile and very effective, facilitating surgery with level low morbidity associated.
http://dx.doi.org/10.1016/j.rpor.2013.03.213
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Objective. A signiﬁcant decrease in lymph node yield after preoperative radio-chemotherapy for rectal cancer compared with
surgery upfront has been described. The goal of this investigation is to determine the prognostic value of the number of lymph
nodes retrieved in patients with LARC treated with preoperative RCT. We also investigated the prognostic value of the local and
regional response after RCT.
Material and methods. Eligible patients presented a diagnosis of proven rectal Adenocarcinoma, stage T2 to T4 and/or N1 to N2.
Patients were treated with pelvic RT (46–50Gy in 2Gy fractions), and 5Fu iv in continuous infusion (225mg/m2) or Capecitabine
(825mg/m2) during RT, followed by TME in 6 weeks after RT-CT. Number of nodes retrieved was analyzed and association with
clinicopathological characteristics were studied. Univariant and multivariant survival analysis were performed.
Results. The mean number of nodes identiﬁed in the surgical specimen was 10 with a range from 0 to 28. 23% of the patients had
at least 7 nodes retrieved, 50% of the patients had at least 10 nodes, 35% at least 12 nodes and 24% at least 14 nodes retrieved. A
signiﬁcant correlation (p=0.001) was found between the number of lymph nodes retrieved and number of lymph nodes affected
(Pearson coefﬁcient 0.37). Retrieval of at least 10 lymph nodes and yT response were independent prognostic factors (p=0.03 and
p=0.005 respectively).
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Conclusions. Less than10 lymphnodes retrieved after RCT is anegative prognostic factor, togetherwith local and regional response.
Further studies are necessary to conﬁrm these ﬁndings.
http://dx.doi.org/10.1016/j.rpor.2013.03.214
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Background. Esophageal cancer (EC) is the eighth most common cancer worldwide. The low survival and poor patient situation
has encouraged the development of multimodal treatments to improve prognosis and treatment tolerance. The role of the chemo
radiotherapy (CRT) has been discussed over the years, supported at present by many randomized studies Purpose: Evaluate the
results of EC according to therapeutic strategy.
Patients and methods. We retrospectively analyzed 52 EC patients with squamous cell carcinoma (SCC) and adenocarcinoma (AC)
treated with CRT between 1999 and 2012. All patients received CRT based on a platinum doublet and concurrent radiotherapy
(50.4Gy, 1.8Gy per fraction over 5–6 weeks or 45Gy, 1.8Gy per fraction over 5–6 weeks). After CRT, patients were subjected to
surgical resection, brachytherapy boost or clinical follow up.
Results. In total, 52 patients with SCC (82.7%) and AC (15.4%) were identiﬁed. Median age was 63 years (range 34–82). In the
diagnosis were 4% T1, 8% T2, 48% T3 and 25% T4 and the 70% had ganglionar metastases. Three types of treatments were
performed: exclusive CRT (57.7%) chemoradiotherapy followed by surgery (25%) or brachytherapy (17.3%). Toxicity grades 3–4
were presented in 25% of pts. The local ﬁrst relapse was as frequent as distant relapse (25% vs. 23%) With a 23 months median
follow-up, there are 15 alive without tumor, 35 deaths and 25 recurrences. Mean progression free survival was 11 months (95%
conﬁdence interval [IC]: 5–12). Mean OS was 23 month 95% IC (17–26). Five-year survival was 26% (95% conﬁdence interval [IC]:
13–41).
Conclusion. CRT is an effective treatment for locally advanced EC, and improvements the survival (OS and progression free
survival), although produces a highly toxicity that requires special cares including inpatient treatment.
http://dx.doi.org/10.1016/j.rpor.2013.03.215
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Introduction and objectives. the kidneys are some of the dose-limiting organs for radiotherapy to upper abdominal cancers.
Radiation-induced kidney damage happens after a long period of time. According to the latest recommendations the mean
dose for both kidneys should not exceed 18Gy. This study, analyzes radiation-induced kidney damage of patients (pts) with
gastric cancer treated with adjuvant radio-chemotherapy (RT-QT) in our center.
Material and methods. Retrospective cohort study of 102 pts with resectable locally advanced gastric cancer treated with adjuvant
RT-QT in our department from August 2003 until June 2012. The median age was 63.7 (range 36–84) and 63.7% were men. The
antrumandpylorus (56.8%)were themost frequent localization followedby gastric corpus (23.5%), fundus (4.9%) and gastroesoph-
ageal junction (10.7%). Median KPS score was 100% (70–100%). For the right kidney the median dose was 14.04Gy (range 2–29),
16.73Gy (1–34) for the left kidney and 15.65Gy (3–32) for both kidneys. Fluoropirimidines in monotherapy was the chemotherapy
used most frequently. All patients were treated with 3D conformal radiotherapy with a median dose of 45Gy (range 18–54)/1.8Gy
using photons of 18MV.
Results. The median follow-up was 36 months (6–101), 23 months for dead pts and 52 months for live pts. The median survival
was 52 months, 55% pts died. 21 pts had a median dose for both kidneys >18Gy and 4 pts developed a decreased glomerular
ﬁltration rate (<60%) and elevated creatinine levels (>1.4mg/dl). In the statistical analysis we did not ﬁnd any signiﬁcant impact
between the median dose for both kidneys and glomerular ﬁltration rate (p=0.198) and creatinine levels (p=0.762).
Conclusion. In our experience, we did not ﬁnd any relationship between the radiation dose received by the kidneys and renal
dysfunction. However, our study had a short follow up and we have to evaluate the dysfunction after 10 years.
http://dx.doi.org/10.1016/j.rpor.2013.03.216
